As of January 22, 2025, AlloVir (ALVR) has a market cap of $46.374 million USD. According to our data, AlloVir is ranked No.8203 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $46.37 M |
-4.46%
|
Dec 31, 2024 | $48.54 M |
-38.24%
|
Dec 29, 2023 | $78.59 M |
-86.74%
|
Dec 30, 2022 | $0.59 B |
-60.36%
|
Dec 31, 2021 | $1.50 B |
-66.34%
|
Dec 31, 2020 | $4.44 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
Atara Biotherapeutics
ATRA
|
$39.68 M |
0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Mesoblast
MESO
|
$2.03 B |
0.000 M
|
Australia
|
Novartis
NVS
|
$196.27 B |
-0.007 M
|
Switzerland
|
Pfizer
PFE
|
$147.40 B |
-0.003 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
Vir Biotechnology
VIR
|
$1.45 B |
0.000 M
|
USA
|
Market Cap | = | ALVR Stock Price | * | ALVR Shares Outstanding |
= | $9.20 | * | 5.04 M | |
= | $46.37 M |